medigraphic.com
ISSN 1527-3172 (Electronic)

2021, Number 3-4

<< Back Next >>

MEDICC Review 2021; 23 (3-4)

Racotumomab in Non-Small Cell Lung Cancer as Maintenanceand Second-Line Treatment

Cáceres-Lavernia HH, Nenínger-Vinageras E, Varona-Rodríguez, LM, Olivares-Romero YA, Sánchez-Rojas I, Mazorra-Herrera Z, Basanta-Bergolla D, Duvergel-Calderín D, Torres-Cuevas BL, del Castillo-Carrillo C

Language: English
References: 49
Page: 21-28
PDF size: 255.81 Kb.


ABSTRACT

INTRODUCTION Racotumomab is a therapeutic vaccine based on a monoclonal anti-idiotypic antibody developed by the Molecular Immunology Center in Havana, Cuba, that is registered in Cuba and Argentina for treatment of non-small cell lung cancer. It induces a specific humoral and cellular immune response against the N-glycolyl GM3 (NeuGcGM3) ganglioside present in tumor cells, thereby provoking the death of these cells.
OBJECTIVE Evaluate racotumomab vaccine use as switch maintenance and second-line therapy for patients with inoperable non-small cell lung cancer in routine clinical practice, outside the framework of clinical studies, and assess the overall survival, stage-specific survival and safety in these patients.
METHODS A descriptive, retrospective study was carried out in patients diagnosed with non-small cell lung cancer not suitable for surgical treatment, who received racotumomab as a part of switch maintenance or second-line treatments. Overall survival was defined from diagnosis and from the first immunization, until death.
RESULTS We included 71 patients treated with racotumomab, 57.7% (41/71) of whom were in stages IIIB and IV of non-small cell lung cancer. Of the patients, 84.5% (60/71) had no adverse events, and 15.5% (11/71) had mild adverse reactions. The median overall survival was 24.5 months, calculated from the first immunization, 17.2 months for those who received racotumomab as switch maintenance and 6.8 months for patients who had progressed after the first line of treatment.
CONCLUSIONS Racotumomab in routine clinical practice prolonged overall survival in patients with non-small cell lung cancer treated in switch maintenance, and in stage IV patients who received the treatment as second-line therapy. The vaccine was well tolerated.


REFERENCES

  1. International Agency for Research on Cancer(IARC); World Health Organization (WHO).Lung. Number of deaths in 2020 both sexes, allages [Internet]. Lyon: International Agency forResearch on Cancer (IARC); 2020 Dec [cited 2021 Jan 12]. 2 p. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf

  2. Globocan. Lung Cancer Fact Sheet [Internet].[cited 2021 Jan 12]. Available at: https//gco.iarc.fr/today/fact-Sheets-cancers/

  3. National Health Statistics and Medical RecordsDivision (CU). Anuario Estadístico de Salud2019 [Internet]. Havana: Ministry of PublicHealth (CU); 2020 [cited 2021 Jan 12]. Availableat: https://fi les.sld.cu/bvscuba/fi les/2020/05/Anuario-Electr%c3%b3nico-Espa%c3%b1ol-2019-ed-2020.pdf. Spanish.

  4. National Comprehensive Cancer Network [Internet].Pennsylvania: National ComprehensiveCancer Network (NCCN); c2021. Guidelinesand. Treatment by Cancer Type. NCCN ClinicalPractice Guidelines in Oncology (NCCN Guideline®). Survivorship v.2; [updated 2019 Dec 23;cited 2020 Feb 1]. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

  5. National Cancer Institute [Internet]. Maryland:National Cancer Institute, National Institutes ofHealth (US); c2021. Cancer types. Lung cancer.Health professional. Non-Small Cell Lung CancerTreatment (PDQ®). Maryland: National CancerInstitute; 2021 [updated 2021; cited 2021 Jan 7].Available at: wwwcancergov/cancertopics/pdq/treatment/non-small-celllung/healthprofessional/page2

  6. Wu YL, Planchard D, Lu S, Sun H, YamamotoN, Kim DW, et al. Pan-Asian Clinical PracticeGuidelines for the management of patients withmetastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO,MOS, SSO and TOS. Ann Oncol. 2019 Feb1;30(2):171–210. DOI:10.1093/annonc/mdy554

  7. Chansky K, Detterbeck FC, Nicholson AG, RuschVW, Vallières E, Groome P, et al. The IASLCLung Cancer Staging Project: external validationof the revision of the TNM stage groupingsin the eighth edition of the TNM classifi cation oflung cancer. J Thoracic Oncol [Internet]. 2017 Jul[cited 2021 Jan 15];12(7):1109–21. Available at:http://dx.doi. org/10.1016/j.jtho.2017.04.011

  8. Goldberg SB. PD-1 and PD-L1 inhibitors: activityas single agents and potential biomarkers in nonsmallcell lung cancer. Am J Hematol Oncol. 2015Sep 13;11(9):10–3.

  9. Awad MM, Gadgeel SM, Borghaei H, Patnaik A,Chih-Hsin Yang J, Powell SF, et al. Long-termoverall survival from KEYNOTE-021 Cohort G:Pemetrexed and Carboplatin with or withoutPembrolizumab as fi rst-line therapy for advancednonsquamous NSCLC. J Thorac Oncol [Internet].2021 Jan [cited 2021 Jan 15];16(1):162–8.Epub 2020 Oct 15. Available at: https://doi.org/

  10. 10.1016/j.jtho.2020.09.01510. Brahmer JR, Rodriguez-Abreu D, RobinsonAG, Hui R, Csőszi T, Fülöp A, et Al. Healthrelatedquality of life for pembrolizumab versuschemotherapy in advanced NSCLC with PD-L1TPS ≥50%: data from KEYNOTE-024. J ThoracOncol. 2017 Jan;12(1 Suppl 1):S8–S9.

  11. Neninger E, Díaz RM, de la Torre A, Rives R,Díaz A, Saurez G, et al. Active immunotherapywith 1E10 anti-idiotype vaccine in patients withsmall cell lung cancer: report of a phase I trial.Cancer Biol Ther. 2007 Feb;6(2):145–50.

  12. Vázquez AM, Hernández AM, Macías A, MonteroE, Gómez DE, Alonso DF, et al. Racomumomab:an anti-idiotype vaccine related to N-glycolyl-containinggangliosides- preclinical and clinical data.Front Oncol. 2012 Oct 23;2:150:1–6.

  13. Disposición 1446 - 13 - ANMAT - AdministraciónNacional de medicamentos, Alimentos y TecnologíaMédica (ANMAT) [Internet]. Buenos Aires:Ministry of Health (AR); 2013 Mar 5 [cited 2021Jan 11]. 32 p. Available at: www.unq.edu.ar/advf/documentos/543e96e1e423a.pdf. Spanish.

  14. Evaluación de tecnologías sanitarias. Recomendacionespara la utilización de racotumumab.Racotumomab en cáncer de pulmón guía derevisión rápida [Internet]. Buenos Aires: Ministryof Health (AR); 2013 [cited 2021 Jan 11]. Availableat: http://www.msal.gob.ar/images/stories/bes/graficos/0000000847cnt-001-Racotumomab2013.pdf. Spanish.

  15. Samraj AN, Pearce OMT, Läubli H, CrittendenAN, Bergfeld AK, Banda K, et al. A redmeat-derived glycan promotes infl ammationand cancer progression. Proc Natl Acad SciUSA [Internet]. 2015 Jan 13 [cited 2021 Jan11];112(2):542–7. Available at: www.pnas.org/cgi/doi/10.1073/pnas.1417508112

  16. Segatori VI, Cuello HA, Gulino CA, Albertó M,Venier C, Guthmann MD, et al. Antibody-dependentcell-mediated cytotoxicity induced by activeimmunotherapy based on racotumomab in nonsmallcell lung cancer patients. Cancer ImmunolImmunother. 2018 Aug;67(8):1285–96.

  17. Hernández AM, Rodríguez N, González JE,Reyes E, Rondón T, Griñán T, et al. Anti-NeuGc-GM3 antibodies, actively elicited by idiotypic vaccinationin nonsmall cell lung cancer patients,induce tumor cell death by an oncosis-like mechanism.J Immunol. 2011 Mar 15;186(6):3735–44.Epub 2011 Feb 7.

  18. Hernández AM, Toledo D, Martínez D, Griñán T,Brito V, Macias A, et al. Characterization of theantibody response against neugcgm3 gangliosideelicited in non-small cell lung cancer patientsimmunized with an anti-idiotype antibody. JImmunol. 2008 Nov 1;181(9):6625–34.

  19. Wang Q, Huang H, Zeng X, Ma Y, Zhao X,Huang M. Single-agent maintenance therapy foradvanced non-small cell lung cancer (NSCLC):a systematic review and Bayesian networkmeta-analysis of 26 randomized controlled trials.Peer J. 2016 Oct 20;4:e2550. DOI: 10.7717/peerj.2550

  20. Alfonso S, Valdés-Zayas A, Santiesteban ER,Flores YI, Areces F, Hernández M, et al. A randomized,multicenter, placebo-controlled clinicaltrial of Racotumomab-Alum vaccine as Switchmaintenance therapy in advanced non–small celllung cancer patients. Clin Cancer Res. 2014 Jul15;20(14):3660–71. DOI: 10.1158/1078-0432.CCR-13-1674

  21. Gajdosik Z. Racotumomab-a novel anti-idiotypemonoclonal antibody vaccine for the treatment ofcancer. Drugs Today (Barc). 2014 Apr;50(4):301–7. DOI: 10.1358/dot.2014.50.4.2116670

  22. Center for State Control of Medicines, Equipmentand Medical Devices (CU) [Internet]. Havana:Center for State Control of Medicines, Equipmentand Medical Devices (CU); c2021. Registro.VAXIRA® (Racotumomab). Reg. No.: B-013-001-L03C; [cited 2021 Mar 7]. Available at:https://www.cecmed.cu/registro/rcp/vaxirar-racotumomab. Spanish.

  23. National Cancer Institute, Divison of CancerTreatment and Diagnosis – DCTD [Internet].Maryland: National Institutes of Health (US);c2021. Cancer Therapy Evaluation Program.Common Terminology Criteria for AdverseEvents (CTCAE) v4.0; [updated 2010 Jun 14; cited2016 Feb 1]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40

  24. Oken MM, Creech RH, Tormey DC, Horton J,Davis TE, McFadden ET, et al. Toxicity andresponse criteria of the Eastern CooperativeOncology Group. Am J Clin Oncol. 1982Dec;5(6):649–55.

  25. Grose D, Devereux G, Milroy R. Comorbidity inlung cancer: important but neglected. A reviewof the current literature. Clin Lung Cancer. 2011Jul [cited 2016 Jan 11];12(4):207–11. DOI:10.1016/j.cllc.2011.03.020

  26. Wu YL, Zhou C, Liam CK, Wu G, Liu X, ZhongZ, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analysesfrom the phase III, randomized, open-label,ENSURE study. Ann Oncol [Internet]. 2015 Sep[cited 2021 Jan 11];26(9):1883–9. DOI: 10.1093/annonc/mdv270. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0923-7534(19)31770-3

  27. Zaki M, Dominello M, Dyson G, Gadgeel S,Wozniak A, Miller S, et al. Outcomes of erderlypatiens who receive combined therapy for LANSCLCin elderly patients clinical lung cancer.2017 Jan;18(1):e21–e6. DOI: http://dx.doi.org/10.1016/j.cllc.2016.07.005

  28. García-Campelo R, Bernabé R, Cobo M, CorralJ, Coves J, Dómine M, et al. SEOM clinicalguidelines for the treatment of non-small cell lungcancer (NSCLC) 2015. Clin Transl Oncol. 2015Dec;17(12):1020–9. DOI: 10.1007/s12094-015-1455-z

  29. Alfonso S, Díaz RM, de la Torre A, SantiestebanE, Aguirre F, Pérez K, et al. 1e10 anti-idiotypevaccine in non-small cell lung cancer: experiencein stage IIIb/IV patients. Cancer Biol Ther. 2007Dec;6(12):1847–52.

  30. Planchard D, Popat S, Kerr K, Novello S, SmitEF, Fraive-Finn C, et al. Metastatic non-smallcell lung cancer: ESMO Clinical Practice Guidelinesfor diagnosis, treatment and follow-up. AnnOncol. 2020 Oct 1;29(Suppl 4):iv192–iv237.

  31. Babu KG, Prabhash K, Vaid AK, Sirohi B, DiwakarRB, Rao R, et al. Nimotuzumab plus chemotherapyversus chemotherapy alone in advancednon-small-cell lung cancer: a multicenter, ramdomized,open-label Fase II study. Onco TargetsTher [Internet]. 2014 Jun 13 [cited 2021 Jan11];7:1051–60. Available at: https://www.dovepress.com/

  32. Gómez RE, Alfonso S, Santiesteban ER,Neninger E, Ardigo ML, Vázquez AM, et al.Active immunotherapy in patients with progressivedisease after fi rst line therapy: Racotumomabexperience. J Clin Oncol [Internet]. 2013May 20 [cited 2016 Jan 11];31(15 Suppl):3086.DOI: 10.1200/jco.2013.31.15_suppl.3086. Availableat: https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.3086

  33. Sokolovska A, Hem SL, Hogen Esch H. Activationof dendritic cells and induction of cd4(+) Tcell differentiation by aluminum-containing adjuvants.Vaccine. 2007 Jun 6;25(23):4575–85.

  34. Hernández AM, Vázquez AM. Racotumomab–alum vaccine for the treatment of nonsmall-cell lung cancer. Expert Rev Vaccines.2015 Jan;14(1):9–20. Epub 2014 Nov 25.DOI: 10.1586/14760584.2015.984691

  35. Pérez L, Estévez D, Gastón Y, Macías A, ViadaCE. Seguridad del Racotumomab en el tratamientode pacientes con cáncer de pulmón decélulas no pequeñas. VacciMonitor [Internet].2013 Jan–Apr [cited 2016 Jan 11];22(1):10–4.Available at: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=40754.Spanish.

  36. Viada C, Fors M, Neninger E, Alfonso S, SantiestebanE, Mendoza I, et al. Seguridad de lavacuna anti-idiotípica 1E10 en pacientes contumores de diversas localizaciones. Bionatura[Internet]. 2016 [cited 2021 Jan 11];1(1):14–9.Available at: https://www.revistabionatura.com/files/2-Seguridad-de-la-vacuna-anti-idiotipica-1E10-en-pacientes-Investigacion.pdf. Spanish.

  37. Eurocare-5. European cancer registry-basedstudy on survival and care of cancer patients:Eurocare [Internet]. Rome: Institute of Health(IT); 2017 [cited 2017 Oct 5]. Available at: http://www.eurocare.it/Eurocare5/ResultsEU5/tabid/90/Default.aspx

  38. Hardtstock F, Myers D, Li T, Cizova D, MaywaldU, Wilke T, et al. Real-world treatment and survivalof patients with advanced non-small celllung cancer: a German retrospective data analysis.BMC Cancer [Internet]. 2020 Mar 30 [cited2021 Jan 11];20(1):260. Available at: https://doi.org/10.1186/s12885-020-06738-z

  39. Moro-Sibilot D, Smit E, de Castro Carpeño J,Lesniewski-Kmak K, Aerts J, Villatoro R, etal. Outcomes and resource use of non-smallcell lung cancer (NSCLC) patients treatedwith fi rst-line platinum-based chemotherapyacross Europe: FRAME prospective observationalstudy. Lung Cancer [Internet]. 2015 May[cited 2021 Jan 11];88(2):215–22. Availableat: https://linkinghub.elsevier.com/retrieve/pii/S0169-5002(15)00118-X

  40. Pirker R, Pereira JR, von Pawel J, KrzakowskiM, Ramlau R, Park K, et al. EGFR expression asa predictor of survival for first-line chemotherapyplus cetuximab in patients with advanced nonsmall-cell lung cancer: analysis of data fromthe phase 3 FLEX study. Lancet Oncol. 2012Jan;13(1):33–42. DOI: 10.1016/S1470-2045(11)70318-7

  41. Arnold BN, Thomas DC, Rosen JE, Salazar MC,Blasberg JD, Boffa DJ, et al. Lung cancer in thevery young: treatment and survival in the NationalCancer Date Base. J Thoracic Oncol [Internet].2016 Jul [cited 2021 Jan 11];11(7):1121–31.Available at: http://dx.doi.org/10.1016/j.jtho.2016.03.023

  42. Perol M, Chouaid C, Pérol D, Barlési F, GervaisR, Westeel V, et al. Randomized, phase III studyof gemcitabine or erlotinib maintenance therapyversus observation, with predefi ned second-linetreatment, after cisplatin-gemcitabine inductionchemotherapy in advanced non-small-celllung cancer. J Clin Oncol [Internet]. 2012 Oct1 [cited 2021 Feb 15];30(28):3516–24. Availableat: https://ascopubs.org/doi/10.1200/JCO.2011.39.9782?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  43. Edelman MJ, Le Chevalier T, Soria JC. Maintenancetherapy and advanced non-small-cell lungcancer: a skeptic’s view. J Thorac Oncol [Internet].2012 Sep [cited 2021 Feb 15];7(9):1331–6.Available at: https://linkinghub.elsevier.com/retrieve/pii/S1556-0864(15)32932-4

  44. Patel JD, Socinski MA, Garon EB, ReynoldsCH, Spigel DR, Olsen MR, et al. Point break: arandomized phase III study of pemetrexed pluscarboplatin and bevacizumab followed by maintenancepemetrexed and bevacizumab versuspaclitaxel plus carboplatin and bevacizumab followedby maintenance bevacizumab in patientswith stage IIIB or IV nonsquamous non-smallcelllung cancer. J Clin Oncol [Internet]. 2013Dec 1 [cited 2021 Jan 11];31(34):4349–57.Available at: https://ascopubs.org/doi/10.1200/JCO.2012.47.9626?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  45. Paz-Ares LG, de Marinis F, Dediu M, ThomasM, Pujol JL, Bidoli P, et al. PARAMOUNT: Finaloverall survival results of the phase III studyof maintenance pemetrexed versus placeboimmediately after induction treatment with pemetrexedplus cisplatin for advanced nonsquamousnon-small-cell lung cancer. J Clin Oncol. 2013Aug 13 [cited 2021 Jan 12];31(23):2895–902.Available at: https://ascopubs.org/doi/10.1200/JCO.2012.47.1102?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  46. Shepherd FA, Dancey J, Ramlau R, Mattson K,Gralla R, O’Rourke M, et al. Prospective randomizedtrial of docetaxel versus best supportivecare in patients with non-small-cell lung cancerpreviously treated with platinum-based chemotherapy.J Clin Oncol. 2000 May;18(10):2095–103.

  47. Rittmeyer A, Barlesi F, Waterkamp D, Park K,Ciardiello F, von Pawel J, et al. Atezolizumab versusdocetaxel in patients with previously treatednon-small-cell lung cancer (OAK): a phase 3,open-label, multicentre randomised controlledtrial. Lancet. 2017 Jan 21;389(10066):255–65.DOI: 10.1016/S0140-6736(16)32517-X

  48. Santiesteban E, Pérez L, Alfonso S, NeningerE, Acosta S, Flores Y, et al. Safety and effi cacyof Racotumomab-Alum vaccine as second-linetherapy for advanced non-small cell lung cancer.Int J Clin Med [Internet]. 2014 Jul [cited 2021Jan 12];5(14):844–50. Available at: http://dx.doi.org/10.4236/ijcm.2014.514113

  49. Hernández M, Neninger E, Santiesteban E,Camacho K, Hernández N, Amador R, et al.Effi cacy of racotumomab or nimotuzumab vsdocetaxel as second line therapy for advancednon-small cell lung cancer patients. Ann Oncol.2018 Oct;29(Suppl 8):viii415. DOI:10.1093/annonc/mdy288 | viii415




2020     |     www.medigraphic.com